WO2011025269A3 - Metformin taurate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same - Google Patents

Metformin taurate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same Download PDF

Info

Publication number
WO2011025269A3
WO2011025269A3 PCT/KR2010/005711 KR2010005711W WO2011025269A3 WO 2011025269 A3 WO2011025269 A3 WO 2011025269A3 KR 2010005711 W KR2010005711 W KR 2010005711W WO 2011025269 A3 WO2011025269 A3 WO 2011025269A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
taurate
metformin
pharmaceutical composition
combined formulation
Prior art date
Application number
PCT/KR2010/005711
Other languages
French (fr)
Korean (ko)
Other versions
WO2011025269A2 (en
Inventor
김성욱
전성수
민창희
구자성
강민석
김용은
Original Assignee
한올바이오파마주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한올바이오파마주식회사 filed Critical 한올바이오파마주식회사
Publication of WO2011025269A2 publication Critical patent/WO2011025269A2/en
Publication of WO2011025269A3 publication Critical patent/WO2011025269A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton

Abstract

The present invention relates to metformin taurate, to a method for preparing same, to a pharmaceutical composition comprising same, and to a combined formulation comprising same. The metformin taurate of the present invention has superior stability, enables easy tabletting, has low toxicity, and exhibits excellent AMPKα-activating effects, and thus can be effectively used in treating glycosuria, diabetes, metabolic syndrome, diabetes complications, menstrual irregularities, hypertension, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome, cancer, myalgia, symptoms of muscle cell cytotoxicity, climacterium and rhabdomyolysis, etc., and provides antioxidant activity.
PCT/KR2010/005711 2009-08-25 2010-08-25 Metformin taurate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same WO2011025269A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0078540 2009-08-25
KR20090078540 2009-08-25

Publications (2)

Publication Number Publication Date
WO2011025269A2 WO2011025269A2 (en) 2011-03-03
WO2011025269A3 true WO2011025269A3 (en) 2011-07-21

Family

ID=43628603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005711 WO2011025269A2 (en) 2009-08-25 2010-08-25 Metformin taurate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same

Country Status (2)

Country Link
KR (1) KR101190953B1 (en)
WO (1) WO2011025269A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102886045A (en) 2005-02-03 2013-01-23 综合医院公司 Method for treating gefitinib resistant cancer
KR101354828B1 (en) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP3135285B1 (en) 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
EP2326329B1 (en) 2008-08-04 2017-01-11 Wyeth LLC Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
DK3000467T3 (en) 2009-04-06 2023-03-27 Wyeth Llc TREATMENT WITH NERATINIB AGAINST BREAST CANCER
ES2729677T3 (en) 2009-11-09 2019-11-05 Wyeth Llc Spheroids of coated drugs and their uses to eliminate or reduce conditions, such as emesis and diarrhea
KR101532944B1 (en) * 2014-06-12 2015-07-02 서울대학교산학협력단 Cell priming method enhancing stem cell transplantation outcome
US20170340584A1 (en) * 2014-12-16 2017-11-30 Jonghyun BYUN Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
WO2017217757A1 (en) * 2016-06-15 2017-12-21 변종현 Modified taurine and preparation method therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092311A1 (en) * 2004-03-12 2005-10-06 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
WO2008112167A1 (en) * 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihypertensive agents for the treatment of diabetic hyperglycemia and diabetic complications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092311A1 (en) * 2004-03-12 2005-10-06 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
WO2008112167A1 (en) * 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihypertensive agents for the treatment of diabetic hyperglycemia and diabetic complications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERONS, C. ET AL.: "Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitusEuropean", EUROPEAN JOURNAL OF CLINICAL NUTRITION, vol. 58, 2004, pages 1239 - 1247 *
ZHANG, F-E ET AL.: "Pharmacokinetics of single metformin hydrochloride and compound metformin-taurine capsules in beagle dogs", SHENYANG YAOKE DAXUE XUEBAO, vol. 26, no. 9, 17 September 2009 (2009-09-17), pages 740 - 744 *

Also Published As

Publication number Publication date
WO2011025269A2 (en) 2011-03-03
KR101190953B1 (en) 2012-10-12
KR20110021690A (en) 2011-03-04

Similar Documents

Publication Publication Date Title
WO2011025269A3 (en) Metformin taurate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same
WO2011025267A3 (en) Metformin methanesulfonate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same
WO2011025271A3 (en) Metformin ascorbate, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same
WO2011025270A3 (en) Metformin caffeic acid salt, method for preparing same, pharmaceutical composition comprising same, and combined formulation comprising same
MX2010002675A (en) Prodrugs to thyroid hormone analogs.
WO2008006715A3 (en) Improvements relating to pharmaceutical compositions
GEP20135786B (en) Pyrrole compounds
GEP20135919B (en) Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors
HK1099032A1 (en) Esters of hyaluronic acid with rhein, process for their preparation and compositions comprising the same
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
AR058098A1 (en) DERIVATIVES OF DICARBOXYL ACIDS AND THEIR USE
TN2012000215A1 (en) Pharmaceutical compositions comprising a g l p -1 agonist and methionine
NZ600439A (en) Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
ECSP088800A (en) DPP IV inhibitor formulations
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2013133685A8 (en) Extract formulations of rhodamnia cinerea and uses thereof
WO2008052044A3 (en) Use of derivatives of propofol for treating diseases associated with oxidative stress
MX2012002876A (en) Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof.
WO2006020358A3 (en) Novel biphenyl compounds and their use
WO2010065289A3 (en) Medical adhesive compositions
UA96618C2 (en) 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
WO2011141791A3 (en) Extended release formulations of desvenlafaxine base
ECSP10010711A (en) 7-SULFANILMETIL-, 7-SULFINILMETIL- AND 7-SULFONILMETILINDOLES REPLACED AND THE USE OF THE SAME
NZ599268A (en) Pharmaceutical compositions of rhein or diacerein made by wet granulation process

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10812282

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10812282

Country of ref document: EP

Kind code of ref document: A2